JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice

about

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.

P2860

Q52590991-4D42634E-9348-4BA1-A809-311DEDC4ED02

P2860

JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice

Item

http://www.wikidata.org/entity/Q36232824

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

JAK2 inhibition has different ...... e neoplasm development in mice

@ast

JAK2 inhibition has different ...... e neoplasm development in mice

@en

type

Item

label

JAK2 inhibition has different ...... e neoplasm development in mice

@ast

JAK2 inhibition has different ...... e neoplasm development in mice

@en

prefLabel

JAK2 inhibition has different ...... e neoplasm development in mice

@ast

JAK2 inhibition has different ...... e neoplasm development in mice

@en

P1476

JAK2 inhibition has different ...... e neoplasm development in mice

@en

P2093

Catherine Lacout

http://www.w3.org/2001/XMLSchema#string

Claudine Moratal

http://www.w3.org/2001/XMLSchema#string

Francisco Adrian

http://www.w3.org/2001/XMLSchema#string

Franck Debeurme

http://www.w3.org/2001/XMLSchema#string

Rebecca G Bagley

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation

Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

Safety evaluation of ruxolitinib for treating myelofibrosis.

P304

2564-2574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCMM.12608

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William Vainchenker

Jean-Luc Villeval

P577

2015-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280122219

http://www.w3.org/2001/XMLSchema#string

P698

26176817

http://www.w3.org/2001/XMLSchema#string

P932

4627562

http://www.w3.org/2001/XMLSchema#string

JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice

about

P2860

P2860

JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932